609 Phase 1/2a dose selection of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with advanced solid malignancies

• Maike Schmidt,
• Sariah Kell,
• Dylan M Glatt,
• Sophia R Majeed

Affiliations

Maike Schmidt

323andMe, South San Francisco, CA, USA

Sariah Kell

323andMe, South San Francisco, CA, USA

Dylan M Glatt

23andMe Inc., South San Francisco, CA, USA

Sophia R Majeed

23andMe Inc., South San Francisco, CA, USA